Navigation Links
VisionGate Receives Strategic Investment from Trinnovate Ventures
Date:3/16/2016

Trinnovate Ventures today announced it will partner with Phoenix-based VisionGate to help accelerate clinical trial programs for both LuCED, a non-invasive diagnostic test targeting early stage lung cancer that responds best to therapy, and Iloprost, a chemoprevention drug for patients who have a pre-cancerous condition of the lungs called dysplasia.

Trinnovate Ventures, a subsidiary of Blue Cross Blue Shield (BCBS) of Arizona, seeks collaborations that promise to ultimately deliver the triple aim of lower healthcare costs, improved patient outcomes and better patient experiences.

“Lung cancer is the number one cancer killer worldwide and is the only cancer whose five-year survival rate has remained virtually unchanged for decades due to the lack of an effective screening test that could significantly impact survival, while other cancers have benefited from a mammogram, Pap smear, colonoscopy, or PSA,” Trinnovate’s Chief Executive Officer and BCBS of Arizona’s Chief Medical Officer Dr. Vishu Jhaveri said. “VisionGate’s accurate LuCED test for lung cancer and dysplasia, along with the company’s exclusive rights to Iloprost, a therapeutic drug that has exhibited in Phase 2 clinical trials the ability to reverse pre-cancerous dysplasia to prevent lung cancer, demonstrates incredible promise.”

As part of this collaboration, Trinnovate Ventures will serve as the lead investor for VisionGate’s $20-million funding round. Having evaluated VisionGate for over a year, Trinnovate’s strategic investment underscores VisionGate’s potential in the marketplace to significantly impact lung cancer mortality and bring a new paradigm for the management of this terrible disease. The partnership will propel the clinical research forward in hopes that Arizonans and people around the world will have quicker access to VisionGate’s potentially life-saving diagnostic and therapeutic innovations.

“Our focus is on finding lung cancer early – when patients are pre-symptomatic, but when treatment is most effective. This is how we start eradicating lung cancer,” VisionGate’s Chairman and CEO Dr. Alan Nelson said. “Our partnership with Trinnovate is pivotal and accelerates our effort to lower healthcare costs through the application of our patented technologies that hold potential to dramatically alter the course of lung cancer, including its prevention.”

For more information about VisionGate, please visit http://www.visiongate3d.com.

###

About VisionGate

VisionGate is a highly patented, commercial stage company focused on dramatically improving the diagnosis and treatment of lung cancer. The Company has a comprehensive offering that includes both a diagnostic to accurately detect lung cancer across all stages as well as a chemoprevention drug to treat dysplasia, or pre-cancerous cells, of the lung. LuCED, the Company’s diagnostic test, is a non-invasive, physician-ordered, take-home sputum test with exquisite sensitivity and specificity across all lung cancer types and stages. LuCED is processed on its proprietary, fully automated 3D cell imaging platform, the Cell-CT, which captures 1,000 cell images per second and measures 594 cell features. LuCED's potential to detect dysplasia, or precancerous cells, makes it a perfect companion to VisionGate’s chemoprevention therapy, currently in Phase IIb trials. For more information, please visit http://www.visiongate3d.com.

About Trinnovate Ventures

Trinnovate Ventures makes investments in healthcare innovations that incorporate three crucial components (the “TRI” in Trinnovate). These pillars of investment are partnership, collaboration and results. Together, these embody the mission statement of Blue Cross Blue Shield of Arizona, which is to provide the best value in health insurance and improve the quality of life for Arizonans.

Read the full story at http://www.prweb.com/releases/2016/03/prweb13264310.htm.


'/>"/>
Source: PRWeb
Copyright©2016 Vocus, Inc.
All rights reserved


Related biology technology :

1. VisionGate Graduation from CEI a Big Win for Phoenix Bioscience Community
2. Lyncean Technologies, Inc. receives $1.1M grant from DOE to develop the Compact Light Source
3. Regeneron Pharmaceuticals’ Industrial Operations & Product Supply Site Receives International Recognition for Operational Excellence
4. DiaCarta Inc. Receives CE Mark for QuantiVirus® HPV E6/E7 mRNA Assay
5. Physicians for Peace Receives Logo Embroidered Lab Coat Donation from Crooked Brook
6. APPLIED PHYSIOLOGY® Receives key US Patent Award for its Unique NAVIGATOR™ Technology
7. Iowa Educator Receives DuPont AgriSCIENCE Award for Teaching Excellence
8. Spinifex Receives $1.5m in R&D Tax Incentive for Research Activities Related to the Discovery of Treatments for Pain
9. Physicians for Peace Resource Mothers Program Receives Fleece Blanket Donation
10. Entia Receives Notices of Allowance for its Ergothioneine and Genetic Transporter Patents from the United States, Canada, and Israel
11. Physicians for Peace Receives Logo Embroidered Polo Shirt Donation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2020)... (PRWEB) , ... June 22, 2020 , ... ... lead glutamine antagonist, DRP-104, will be presented June 22-24 during the American Association ... of DRP-104; and, the other profiles the potent, consistent single agent activity in ...
(Date:6/11/2020)... ... June 08, 2020 , ... Greffex, a leading ... use of proprietary clean viral vectors, recently announced a key manufacturing agreement with ... platform is the world’s most successful gene therapy delivery vehicle (vector) with broad ...
(Date:6/11/2020)... ... ... Reducing carbon emissions has been and will continue to be a major topic of ... reduce CO2 is something we can’t avoid. , To protect the environment, oil ... are created from recycled cooking oil or crops. Unfortunately, these sources are not sustainable. ...
(Date:5/30/2020)... ... 2020 , ... Medrio, Inc., the leading provider of eClinical ... Cytovale, Inc., a medical technology company dedicated to revolutionizing diagnostics for conditions like ... in (FPI) in just seven days. The Cytovale technology will allow patients with ...
Breaking Biology Technology:
(Date:6/5/2020)... MURRIETA, Calif. (PRWEB) , ... June 04, 2020 , ... ... , has filed a new patent application for simplified sample preparation for Next ... technology that will greatly reduce cost, time, and complexity of sample preparation. , “I ...
(Date:6/2/2020)... ... June 02, 2020 , ... ... and RFID labeling software developer and solutions provider, today reported that the ... labeling accuracy and compliance by 100%, resulting in greater efficiency for global ...
(Date:5/28/2020)... INDIANAPOLIS (PRWEB) , ... May 27, 2020 , ... ... of hc1 Workforce Advisor™ , a solution that uniquely combines lab testing ... to help employers systematically support the ongoing health and safety of employees returning ...
Breaking Biology News(10 mins):